Abemaciclib in the Treatment of Early-Stage Hormone Receptor-Positive Breast Cancer – Anmol Singh, MD
Endocrine therapy remains a mainstay in the treatment of early-stage hormone receptor-positive breast cancer. However, oncologists continue to work on improving the risk of recurrence in patients whose tumors exhibit high-risk features, such as a larger size or lymph node involvement. The MonarchE trial, a randomized phase 3 trial in adults, examined how the addition […]
Enhancing Lung Cancer Treatment: The Promise of Perioperative Immunotherapy – Samantha DiBenedetto, MD
Introduction: Lung cancer remains one of the most challenging and life-threatening diseases; however, several exciting treatment advances show promising benefits. A recent study in which Virginia Cancer Specialists participated under the research leadership of Dr. Alex Spira, the AEGEAN trial, was published in the New England Journal of Medicine (NEJM) earlier this month and has shed light […]
New Advances in Early-Stage Lung Cancer Treatment – Samantha DiBenedetto, MD
Lung cancer poses a significant healthcare challenge in the United States, with approximately 237,000 individuals newly diagnosed each year. Although the majority of cases are found at an advanced stage, approximately 25-35% of cases are detected early where surgery and chemotherapy can be effective treatment options. Despite these efforts, disease recurrence rates remain high, impacting […]
Advancements in Treating Chemotherapy Side Effects – A New Standard of Care for Preventing Hand-Foot Syndrome – Igryl S. Cordero, MD
Patients undergoing treatment for breast or gastrointestinal cancers with the chemotherapy drug capecitabine (Xeloda®) may develop hand-foot syndrome (HFS). A common treatment side-effect, HFS can lead to redness, swelling, skin peeling, and sometimes painful blisters on the palms and soles. Although the syndrome is not life-threatening, it can cause significant discomfort and negatively impact a […]
Investigational Inhibitor of Active RAS Shows Clinical Promise – Alexander I. Spira, MD, PhD, FACP
Investigational Inhibitor of Active RAS Shows Clinical Promise – The therapy uses a different mechanism than approved KRAS G12C inhibitors and targets multiple RAS mutations beyond KRAS G12C
Virginia Cancer Specialists Welcomes Two New Medical Oncologists to Gainesville and Woodbridge Locations
Igryl Cordero, MD, and Anmol Singh, MD, have joined the practice to provide expert care to the community in Northern Virginia. Virginia Cancer Specialists, a premier provider of leading-edge cancer care in Northern Virginia, is pleased to welcome Igryl Cordero, MD, and Anmol Singh, MD, to our medical oncology team. Dr. Cordero and Dr. Singh […]
Landmark Non-Small Cell Lung Cancer Study – Clinically Meaningful Improvement and Progression Free Survival, Alexander I. Spira, MD, PhD, FACP
Virginia Cancer Specialists Research Institute – Landmark “Non-Small Cell Lung Cancer Study” – Alexander I. Spira, MD, PhD, FACP Planned interim overall survival analysis showed a trend favoring the combination of RYBREVANT® and lazertinib compared to osimertinib* First pivotal study to show a clinically meaningful benefit in a chemotherapy-free regimen versus osimertinib – See the […]
Virginia Cancer Specialists Welcomes New Medical Oncologist to Fairfax Location
Samantha DiBenedetto, MD, has joined the practice to provide expert cancer care to the community in Northern Virginia. Virginia Cancer Specialists, a premier provider of leading-edge cancer care in Northern Virginia, is pleased to welcome Samantha DiBenedetto, MD, to our medical oncology team. Dr. DiBenedetto joins a passionate team of experts delivering progress and hope […]